Cargando…

A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer

BACKGROUND: Prostate cancer is the most common malignant tumor associated with male reproductive system. OBJECTIVE: The existing eligible randomized controlled trials (RCTs) were critically appraised for the safety and effectiveness of CHM for prostate cancer. METHODS: A literature search was conduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Huijuan, Mu, Yujie, Li, Xun, Wang, Yuyi, Chen, Shiuan, Liu, Jian-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973922/
https://www.ncbi.nlm.nih.gov/pubmed/27490098
http://dx.doi.org/10.1371/journal.pone.0160253
_version_ 1782446474560274432
author Cao, Huijuan
Mu, Yujie
Li, Xun
Wang, Yuyi
Chen, Shiuan
Liu, Jian-ping
author_facet Cao, Huijuan
Mu, Yujie
Li, Xun
Wang, Yuyi
Chen, Shiuan
Liu, Jian-ping
author_sort Cao, Huijuan
collection PubMed
description BACKGROUND: Prostate cancer is the most common malignant tumor associated with male reproductive system. OBJECTIVE: The existing eligible randomized controlled trials (RCTs) were critically appraised for the safety and effectiveness of CHM for prostate cancer. METHODS: A literature search was conducted by using PubMed, CENTRAL, CNKI, CBM, VIP and Wanfang databases until August 2015. RCTs of CHM or CHM plus conventional medicine for prostate cancer patients were included. The primary outcomes appraised were survival time, time to progression and quality of life. The risk of bias assessment according to the Cochrane Handbook was used to evaluate the methodological quality of the included trials. Revman 5.3 software was used for data analyses. Risk ratio and mean difference (MD) with a 95% confidence interval (CI) were used as effect measures. Meta-analysis was to be used if sufficient trials without obvious clinical or statistical heterogeneity were available. RESULTS: A total of 17 RCTs involving 1224 participants were analyzed. One trial was about CHM comparing to no treatment. The remaining 16 trials used CHMs as adjunctive treatment for endocrine therapy. Due to the poor quality of methodologies of most trials, only limited evidence showed that a combination of CHM and endocrine therapy might be more effective in restraining the development of the disease (MD 10.37 months, 95%CI 9.10 to 11.63 months), increasing patients’ survival time (7–15 months) or improving patients’ performance status, when compared to endocrine therapy alone (Karnofsky performance scale average changed 15 scores between groups). No severe adverse event was reported related to CHM. CONCLUSION: Due to the insufficient quality of trials that were analyzed, it is not appropriate to recommend any kind of CHMs in treating prostate cancer at the present time. Well-designed trials with high methodological quality are needed to validate the effect of CHMs for patients with prostate cancer.
format Online
Article
Text
id pubmed-4973922
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49739222016-08-18 A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer Cao, Huijuan Mu, Yujie Li, Xun Wang, Yuyi Chen, Shiuan Liu, Jian-ping PLoS One Research Article BACKGROUND: Prostate cancer is the most common malignant tumor associated with male reproductive system. OBJECTIVE: The existing eligible randomized controlled trials (RCTs) were critically appraised for the safety and effectiveness of CHM for prostate cancer. METHODS: A literature search was conducted by using PubMed, CENTRAL, CNKI, CBM, VIP and Wanfang databases until August 2015. RCTs of CHM or CHM plus conventional medicine for prostate cancer patients were included. The primary outcomes appraised were survival time, time to progression and quality of life. The risk of bias assessment according to the Cochrane Handbook was used to evaluate the methodological quality of the included trials. Revman 5.3 software was used for data analyses. Risk ratio and mean difference (MD) with a 95% confidence interval (CI) were used as effect measures. Meta-analysis was to be used if sufficient trials without obvious clinical or statistical heterogeneity were available. RESULTS: A total of 17 RCTs involving 1224 participants were analyzed. One trial was about CHM comparing to no treatment. The remaining 16 trials used CHMs as adjunctive treatment for endocrine therapy. Due to the poor quality of methodologies of most trials, only limited evidence showed that a combination of CHM and endocrine therapy might be more effective in restraining the development of the disease (MD 10.37 months, 95%CI 9.10 to 11.63 months), increasing patients’ survival time (7–15 months) or improving patients’ performance status, when compared to endocrine therapy alone (Karnofsky performance scale average changed 15 scores between groups). No severe adverse event was reported related to CHM. CONCLUSION: Due to the insufficient quality of trials that were analyzed, it is not appropriate to recommend any kind of CHMs in treating prostate cancer at the present time. Well-designed trials with high methodological quality are needed to validate the effect of CHMs for patients with prostate cancer. Public Library of Science 2016-08-04 /pmc/articles/PMC4973922/ /pubmed/27490098 http://dx.doi.org/10.1371/journal.pone.0160253 Text en © 2016 Cao et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cao, Huijuan
Mu, Yujie
Li, Xun
Wang, Yuyi
Chen, Shiuan
Liu, Jian-ping
A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer
title A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer
title_full A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer
title_fullStr A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer
title_full_unstemmed A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer
title_short A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer
title_sort systematic review of randomized controlled trials on oral chinese herbal medicine for prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973922/
https://www.ncbi.nlm.nih.gov/pubmed/27490098
http://dx.doi.org/10.1371/journal.pone.0160253
work_keys_str_mv AT caohuijuan asystematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT muyujie asystematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT lixun asystematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT wangyuyi asystematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT chenshiuan asystematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT liujianping asystematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT caohuijuan systematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT muyujie systematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT lixun systematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT wangyuyi systematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT chenshiuan systematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer
AT liujianping systematicreviewofrandomizedcontrolledtrialsonoralchineseherbalmedicineforprostatecancer